AUTIFONY THERAPEUTICS LIMITED
Get an alert when AUTIFONY THERAPEUTICS LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-06-30 (in 1mo)
Last filed for 2024-09-30
Confirmation statement due
2027-03-11 (in 10mo)
Last made up 2026-02-25
Watchouts
None on the register
Cash
£15M
+226.6% vs 2023
Net assets
£16M
+191% vs 2023
Employees
31
+29.2% vs 2023
Profit before tax
£11M
+289.3% vs 2023
Name history
Renamed 1 time since incorporation
- AUTIFONY THERAPEUTICS LIMITED 2011-06-01 → present
- NEWINCCO 1091 LIMITED 2011-02-25 → 2011-06-01
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · latest reflected 2024-09-30
| Metric | Trend | 2023-09-30 | 2024-09-30 |
|---|---|---|---|
| Turnover | £1,369,894 | £19,315,793 | |
| Operating profit | -£5,663,004 | £10,302,911 | |
| Profit before tax | -£5,616,644 | £10,632,320 | |
| Net profit | -£4,693,204 | £10,743,550 | |
| Cash | £4,512,821 | £14,739,323 | |
| Total assets less current liabilities | — | — | |
| Net assets | £5,618,187 | £16,350,489 | |
| Equity | £5,618,187 | £16,350,489 | |
| Average employees | 24 | 31 | |
| Wages | £1,972,206 | £2,465,910 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-09-30 | 2024-09-30 |
|---|---|---|---|
| Operating margin | -413.4% | 53.3% | |
| Net margin | -342.6% | 55.6% | |
| Gearing (liabilities / total assets) | 21.0% | 11.5% | |
| Current ratio | 4.78x | 8.49x | |
| Interest cover | -505.90x | 449.75x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- IFRS
- Reporting scope
- Consolidated group
- Auditor
- RSM UK Audit LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's or the parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”
Group structure
- AUTIFONY THERAPEUTICS LIMITED · parent
- Autifony Srl 100%
- Autifony Alpha Limited 100%
Significant events
- “On 23rd May 2025, the Company disposed of its investment in its subsidiary company Autifony Srl.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
6 active · 10 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| SELIN, Hannah Louise | Secretary | 2025-05-07 | — | — |
| AL-HALLAQ, Rana | Director | 2019-04-15 | Jun 1975 | American |
| BERRIMAN, John Edward | Director | 2011-05-23 | Apr 1948 | British |
| BINGHAM, Catherine Elizabeth, Dame | Director | 2011-08-19 | Oct 1965 | British |
| LARGE, Charles Henry | Director | 2011-05-23 | May 1967 | British |
| IP2IPO SERVICES LIMITED | Corporate Director | 2018-03-12 | — | — |
Show 10 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| OLSWANG COSEC LIMITED | Corporate Secretary | 2011-02-25 | 2011-05-23 |
| ALVARO, Giuseppe | Director | 2011-05-23 | 2011-08-19 |
| BAXTER, Allan | Director | 2011-08-19 | 2015-01-27 |
| BHAMAN, Maina | Director | 2011-08-19 | 2017-12-15 |
| JONES, Elaine, Dr | Director | 2013-02-14 | 2019-04-15 |
| MACKIE, Christopher Alan | Director | 2011-02-25 | 2011-05-23 |
| PANDE, Atul Chandra, Dr | Director | 2014-04-01 | 2024-01-31 |
| SONI, Bobby G., Dr | Director | 2017-12-15 | 2018-03-12 |
| OLSWANG DIRECTORS 1 LIMITED | Corporate Director | 2011-02-25 | 2011-05-23 |
| OLSWANG DIRECTORS 2 LIMITED | Corporate Director | 2011-02-25 | 2011-05-23 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Pfizer Inc | Corporate entity | Shares 25–50% | 2021-11-01 | Ceased 2023-01-12 |
| Svls Life Sciences Fund V Lp | Corporate entity | Shares 25–50% | 2016-04-06 | Ceased 2021-11-01 |
| Touchstone Innovations Businesses Llp | Corporate entity | Shares 25–50%, Voting 25–50% | 2016-04-06 | Active |
Filing timeline
Last 20 of 138 total filings
Material constitutional events — rename, articles re-file, resolution
- 2025-10-17 RESOLUTIONS Resolution
- 2024-06-28 MA Memorandum articles
- 2024-06-28 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-03-24 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2026-03-20 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2026-03-03 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2025-10-17 | SH19 | capital | Capital statement capital company with date currency figure | |
| 2025-10-17 | SH20 | capital | Legacy | |
| 2025-10-17 | CAP-SS | insolvency | Legacy | |
| 2025-10-17 | RESOLUTIONS | resolution | Resolution | |
| 2025-06-13 | AA | accounts | Accounts with accounts type group | |
| 2025-05-07 | AP03 | officers | Appoint person secretary company with name date | |
| 2025-03-04 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-07-29 | SH01 | capital | Capital allotment shares | |
| 2024-07-29 | SH01 | capital | Capital allotment shares | |
| 2024-07-02 | AA | accounts | Accounts with accounts type group | |
| 2024-06-28 | MA | incorporation | Memorandum articles | |
| 2024-06-28 | RESOLUTIONS | resolution | Resolution | |
| 2024-03-05 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-02-27 | SH01 | capital | Capital allotment shares | |
| 2024-02-08 | TM01 | officers | Termination director company with name termination date | |
| 2023-11-23 | SH01 | capital | Capital allotment shares | |
| 2023-10-12 | SH01 | capital | Capital allotment shares |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 9
- Capital events
- 4
- Officers appointed
- 1
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-09-30 vs 2023-09-30
-
Turnover
+1,310%
£1,369,894 £19,315,793
-
Cash
+226.6%
£4,512,821 £14,739,323
-
Net assets
+191%
£5,618,187 £16,350,489
-
Employees
+29.2%
24 31
-
Operating profit
+281.9%
-£5,663,004 £10,302,911
-
Profit before tax
+289.3%
-£5,616,644 £10,632,320
-
Wages
+25%
£1,972,206 £2,465,910
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers